Latest Woolsey Pharmaceuticals News & Updates
See the latest news and media coverage for Woolsey Pharmaceuticals. We track all announcements, press releases, and industry mentions in real time, all in one place.
Latest news about Woolsey Pharmaceuticals
Company announcements
-
Woolsey Pharmaceuticals completes Series B extension
Funds advance BRAVYL ALS program. Completed high-dose enrollment; NfL decreased 15%; TDP-43 pathology reduced. Data expected June 2025.
-
Woolsey Pharmaceuticals secures U.S. patent claims for BRAVYL in ALS
USPTO grants claims covering fasudil treatment of ALS and NfL reduction. It adds to existing patents on formulations and sporadic ALS.
-
Woolsey reveals BRAVYL reduces TDP-43 spread in ALS patients
Lab findings show 60% reduction in aggregation and cytoplasmic redistribution after 6 months treatment. Presented at ALS/MND Symposium.
-
Woolsey Pharmaceuticals completes patient recruitment for high-dose ALS study cohort
Recruitment finished for 300 mg/day cohort (n=31) in REAL study of BRAVYL® after promising results at 180 mg/day, including 15% NfL decrease. Results expected mid-2025.
Media coverage
Track Woolsey Pharmaceuticals and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Trending companies
Discover what's making headlines across other trending companies.
Sironax
Aperture Therapeutics
Attentive
Klaviyo
Twilio
Insider One
Zeta Global
Iterable
Braze
Optimove
Bluecore
BlueConic
Amperity
Wero
BLIK
EPI
Swish
Affirm
Brite Payments
TCS
Overview Energy
Adfin
Ineffable Intelligence
Mechanize
Hexatronic
Alimak Group
Lindab Group
NYAB
Noon Energy
Nordan AI
Mips
Vexlum
Asker Healthcare Group
FAKRO